Photocure $PHO setting up for IHS?An average Q3 report for Photocure today giving some selling action, painting up the framework for a nice inverted head & shoulders formation within the long uptrend of the stock.
0IMT trade ideas
Photocure $PHO well that escalated quicklyPhotocure breaking free upwards from important 100 NOK resistance and heads for analyst BUY recommendations at 130+
Photocure $PHO Partners with Asieris on Hexvix in ChinaPhotocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan
Agreement Expands Photocure’s Hexvix®/Cysview® Franchise Footprint to over 30 Countries
Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that it has entered into a partnership agreement with Asieris MediTech Co., Ltd. (Asieris), a division of Jiangsu Yahong Meditech Co., Ltd., whereby Asieris has obtained exclusive rights to register and commercialize Hexvix® in Mainland China and Taiwan.
Photocure $PHO close at 100 NOK at all time high market cap100 NOK the last major resistance in the chart.
Ready to break out from Triangle formation.
Nice EMA 20 / 100 Bounce
Strong Analyst BUY consensus from DNB Markets, ABG, Norne etc.
PHOTOCURE buying opportunitySo I can be quick on Photocure.
We are in a nice long uptrend, which is currently hitting resistance, forming an ascending triangle.
The only sure strategy here is to wait for a break and retest of this triangle.
Analyst increase Photocure $PHO price target to 130 (125) ABG Sundal Collier: Photocure - Q3: a solid stepping stone towards expansion
Q3 results due 10 November US recovery and EU commercialisation in the spotlight Tweaking near term ests. – DCF TP up to NOK 130 (125)
Photocure Self Explanatory.
Target flexible (Calculated Wave 1 = Wave 5). Prioritize channel resistance.
Photocure Long (retracement first)The whole stock market is experiencing the same type of "crack" as it did back in Feb/March, now being fueled by a Covid second wave and uncertainty around the US elections. Photocure's RSI is approaching its year low levels in March. The down period in March lasted for about 1 month. The length of this down period will be more uncertain depending on the outcome of the election. Regardless, I see Photocure retracing to between 71 and no more than 57NOK (which would equal a retracement of 0.786, same as in feb/march) before turning around and going to new heights. Currently the company's market valuation is around 2bn NOK. A price target of between 180-220 NOK in May 2021 would give it a market value of 5-6bn NOK which is not unlikely at all. 50 day MA will most likely cross down the 250 MA at first. When it crosses back up, we'll know this company will go to new heights.
Photocure $PHO test breakout from ascending triangle formationLook for increased trading volume confirming breakout above NOK 94
Photocure $PHO trading above previous top as shorts reduce posThe Photocure share price has been increasing steadily even in the face of short sellers thas has been adding to their positions in Photocure stock for three weeks straight.
With the stock now trading above the last top, longs will be hoping to see a short squeeze effect in the the price development.
Recent 50SMA / 200SMA golden cross.
Top 20 ownership increasing steadily.
Photocure $PHO trading above 50 and 200 SMA after Q2 reportRecent oversubscribed equity offerings done at 76 and 65,5 NOK after repurchasing global Hexvix ownership from Ipsen now securely in the money.
Recent newsflow:
13.08.2020 Photocure appoints Genotests as exclusive partner for Hexvix in Chile
08.07.2020 Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)
01.07.2020 Photocure appoints Susanne Strauss as Vice President and General Manager of Europe
24.06.2020 Private placement successfully placed - NOK 76
27.04.2020 Private placement successfully placed - NOK 65,5
27.04.2020 PHOTOCURE REGAINS WORLDWIDE RIGHTS OF HEXVIX
Analysts see 100% upside potential in Photocure $PHONorne securities july 31st: BUY 150 NOK
ABG Sundal Collier july 1st: BUY 120 NOK
Edison may 13th: BUY 109 NOK
Photocure $PHO.OL testing breakout from 200 and 50 moving avgIn july analysts predicted up to 100% upside in $PHO stock.
Still significant amount of short positions reported.
Largest owner in Photocure $PHO.OL offloading whole positionLargest owner in Photocure OSL:PHO apparently being forced to dump the whole position in the stock in the course of a few days, giving the stock extra momentum to the downside.
Updated list of shareholders show influx of US actors.
twitter.com
Photocure $PHO.OL trade above last major resistance on US patentPatent covering the use of Blue Light Cystoscopy (BLC®) with Hexvix as neoadjuvant* therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy.
Early stage study results have shown an antitumor effect and induced systemic immune effects of hexaminolevulinate (HAL) and blue light in an orthotopic model of rat bladder cancer. Photocure has the intention to further investigate Hexvix for its therapeutic effect and the patent is a result of Photocure’s continued focus on securing intellectual property rights for its research results and pipeline activities.
The patent was issued on 11 February 2020 and will expire in December 2036.
* Neoadjuvant therapy: treatment (such as chemotherapy) administered before primary cancer treatment (such as surgery) to enhance the outcome of primary treatment
Photocure OSL:PHO IR news release: photocure.com
Photocure $PHO.OL stock trade above resistance, close at 5yr hghRecent news by OSL:PHO :
Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
photocure.com
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
photocure.com
Further improvements for US reimbursements for Cysview from january 2020:
photocure.com
Technical analysis:
Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
Photocure $PHO.OL stock could break out after Q3 presentationPhotocure OSL:PHO presented Q3 numbers with top line numbers just a hint weaker than consensus, but with the strongest quarterly growth rate in deployed cystoscopes ever noted.
The stock is currently trading above earlier support, and a move through NOK 60 could trigger a strong BUY signal.
Q3 Report:
photocure.com
Q3 webcast in english with CEO Daniel Schneider of Photocure:
webtv.hegnar.no
OSE3520GI transformFishertransform of OSE3520GI index and constituents. A bit messy, no clue how to add labels with pinescript.
Edison updated $PHO price target 70 NOK after Cevira partnershipOSL:PHO
Company press release about partnership deal URL:
twitter.com
Edison analyst update URL:
www.edisongroup.com
Photocure $PHO.OL stock pullback after Q2 is chance to buyPhotocure $PHO.OL OSL:PHO presented Q2 2019 numbers today, with most numbers landing very close to expectations.
Webcast: webtv.hegnar.no
Press release: newsweb.oslobors.no
Armchair Healthcare podcast interview with CEO Dan Schneider: twitter.com
Photocure $PHO.OL renewed breakout watch ahead of Q2 reportInvestors are eagerly awaiting Photocures OSL:PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal.
Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could easily mean a pullback well below the NOK 50 level, which mean that an entry ahead of the upcoming Q2 presentation should be made with a keen eye on risk management.
Recent Edison Analysis after Cevira Deal announcement, BUY target price 70 NOK:
www.edisongroup.com
Photocure $PHO.OL boost on chinese partnership dealPhotocure OSL:PHO today released news of a outlicensing of the Cevira franchise for commercialization, giving the stock a boost, possibly regaining foothold above the SMA50 and SMA200.
Press release
photocure.com
